OUR ACTIVITIES AND INITIATIVES
The Schoolchildren against malaria program, in Burkina Faso.
CONCRETE ACTIONS TO BROADLY INFORM, PROTECT AND TREAT
Malaria is the deadliest parasitic disease in the world. Every two minutes, in Africa, a child dies of malaria. We address this epidemic through prevention, treatment and information. For the past fifteen years, Sanofi has set up a partnership strategy which aims to provide drugs adapted to patients’ needs, at affordable prices, and to support stakeholders in the field. The first anti-malarial treatment produced by a public-private partnership, ASAQ Winthrop®, was developed with a non-profit R&D organization, Drugs for Neglected Diseases initiative, which meets WHO recommendations. Not covered by a patent, the drug is available to the public sector at discounted rates—at times low enough where there is zero profit and zero loss. More than 400 million treatments have been distributed since 2007, mainly in Africa. Sanofi also develops training and information tools with its partners. The Schoolchildren against malaria program, for example, has reached out to more than 8 million children in Africa.